Why the study?
Does the carriage of the TBS1 gene polymorphism AA affect the risk of clopidogrel resistance and cardiovascular events in patients with coronary heart disease taking clopidogrel?
Cohort (n=250)
Does the carriage of the TBS1 gene polymorphism AA affect the risk of clopidogrel resistance and cardiovascular events in patients with coronary heart disease taking clopidogrel?
The carriage of the slow AA allele of the TBS1 gene may serve as a clinically significant protective factor against cardiovascular events in patients with coronary heart disease on clopidogrel.
AIM: To analyze the influence of pharmacogenetic factors on the risk of clopidogrel resistance and cardiovascular events during 18-months follow-up. SUBJECTS AND METHODS: Two hundred and fifty patients taking clopidogrel were examined. Platelet function was determined by optical aggregometry. Thromboxane A synthase 1 (TBS1) gene polymorphism was investigated in all the patients. The impact of TBS1 gene polymorphism on the risk of clopidogrel resistance and cardiovascular events was analyzed during 18 months of follow-up. RESULTS: The carriage of TBS1 gene polymorphism AA was shown to affect the risk of clopidogrel resistance. Cardiovascular complications significantly less frequently occurred in TBSI gene polymorphism AA carriers during 18 months. CONCLUSION: The carriage of a slow AA allele of the'TBS1 gene is suggested to be a clinically significant protective factor in the secondary prevention of coronary heart disease
No takes yet. Share an insight, caveat, or question.
Kopylov et al. (2015) conducted a cohort in Coronary heart disease (n=250). Thromboxane A synthase 1 (TBS1) gene polymorphism AA vs. Non-AA carriers was evaluated on Clopidogrel resistance and cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: